Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$23.42 - $62.58
Next Earnings Date
May 01 2025
Next Earnings Date
May 01 2025
Last Price
Market Cap | $1.67B |
EV | $192.28M |
Shares Outstanding | 57.30M |
Beta | 0.83 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $53.17 |
P/E 2025E | - |
P/Revenue 2025E | 33.59x |
Revenue | - |
EPS | -24.00% |
Operating Cash Flow | 1.50% |
Free Cash Flow | 1.80% |
Revenue | 109.40% |
EPS | - |
Operating Cash Flow | -9.90% |
Free Cash Flow | 14.90% |
Gross Margin 2025E | 88.33% |
Net Profit Margin 2025E | -907.66% |
ROE 2025E | -34.03% |
ROCE 2024 | 57.29% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Agios Pharmaceuticals, Inc.
AGIO
Sector
Healthcare
Industry
Biotechnology
CEO
Goff, Brian
Employees
487
Website
www.agios.comIPO Date
2013-07-24
Headquarters
88 Sidney Street, Cambridge, Massachusetts, 02139, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved